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Abstract
During April 2010 and June 2010, 334 Enterobacteriaceae isolates
from 590 participants (outpatients, inpatients, inpatient carers,
hospital workers and members of their households) were
collected from faecal samples. Based on b-lactamase pattern,
origin of strains and the relationship between participants, 44
isolates of extended-spectrum b-lactamase (ESBL)-producing
Escherichia coli and Klebsiella pneumoniae were selected from 44
participants (in Ngaoundere Protestant Hospital and Ngaoundere
Regional Hospital, Cameroon). To determine the relatedness of
bacterial strains, these isolates were ﬁngerprinted using the
automated, repetitive-sequenced-based PCR-based DiversiLab
system. Subsequently, E. coli isolates that had undergone Diver-
siLab analysis were examined with respect to their phylogenetic
group and detection of the ST131 clone to shed light on the
epidemiology of these isolates in the Ngaoundere hospitals. The
prevalence of faecal carriage of ESBL-producing Enterobacteriaceae
among the study participants was 54.06%. According to participant
groups, the prevalence of faecal carriage was also high (outpatients
45%; inpatients 67%; inpatient carers 57%; hospital workers 44%;
and members of their households 46%). Analysis of the molecular
epidemiology of ESBL-producing E. coli and K. pneumoniae showed
a close relationship of the isolates between related and non-
related individuals. In addition, DiversiLab results of E. coli
identiﬁed four related isolates (4/22) from cluster III belonging
to the epidemiologically important clone ST131. Our results
highlight the importance of outpatients, inpatients, their carers,
hospital workers and their families as reservoirs of ESBL-
producing Enterobacteriaceae
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Studies have shown the presence of extended-spectrum b-
lactamase-producing Enterobacteriaceae (E-ESBLs) in Camer-
oon, not only in hospitals but also in the community [1–4].
However, although E-ESBLs are present and increasingly
prevalent in the country, little is known about their dissem-
ination. To ﬁnd out the prevalence of faecal carriage of E-ESBLs
and how they are spreading, an epidemiological study of
E-ESBLs involving outpatients, inpatients, inpatient carers,
hospital workers and members of their households was
performed in hospitals in Ngaoundere, Cameroon. Written
informed consent was obtained from all participants. Partic-
ipants’ characteristics are shown in Table 1.
A total of 334 Enterobacteriaceae were isolated on two
selective media, Drigalski and MacConkey agars, supplemented,
respectively with cefotaxime and ceftazidime. Detection of
ESBL producers was carried out by the double-disc synergy test
[5]. Susceptibility of the isolates to antibiotics was determined
using the Vitek system (bioMerieux, Marcy l’Etoile, France). All
the presumptive ESBL producers were further analysed by PCR
aimed at detecting ESBL genes (one isolate of each morphotype
from each patient). PCR ampliﬁcation of bla genes (blaTEM,
blaSHV, blaOXA and blaCTX-M) was performed using primers and
methods described previously [6,7] (Table 2). All PCR prod-
ucts were sequenced using a 3100 ABI Prism Genetic Analyser
(Applied Biosystems, Foster City, CA, USA). Sequence align-
ment and analyses were performed online using the BLAST
program available at the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov).
To determine the relatedness of bacterial strains, 44
isolates (22 Escherichia coli and 22 Klebsiella pneumoniae) were
recovered from 44 participants and ﬁngerprinted using the
automated repetitive-sequence-based PCR DiversiLab system
(bioMerieux). The strains were selected based on their
b-lactamase pattern, their origin and the relationship between
participants. The relationships between repetitive-sequence-
based PCR proﬁles were designated as recommended by the
manufacturer: different, 3+ band differences (similarity <95%);
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similar, 1–2 band differences (similarity 95–97%); and indistin-
guishable, no band differences (similarity >97%).
Subsequently, the 22 E. coli isolates that had undergone
DiversiLab analysis were investigated by a series of PCRs [8–
10] to determine the phylogenetic groups (A, B1, B2 and D),
the presence of ISEcp1 elements and the aac(6′)-Ib-cr variant
(the gene that can induce resistance to aminoglycoside and
ﬂuoroquinolone simultaneously).
All 22 E. coli ESBL-producing isolates were screened for
sequence type 131 (ST131) using a PCR for the pabB allele,
described by Clermont et al. [11]. Multilocus sequence typing
was performed on positive pabB isolates using the Achtman
typing scheme (http://www.mlst.ucc.ie/mlst/dbs/Ecoli).
Statistical analysis was performed with EPI INFO version 3.5.3.
Fisher’s exact test, when appropriate, was used for the
univariate comparison of all variables. A p value of p <0.05 was
considered to be statistically signiﬁcant.
The overall prevalence of faecal carriage of E-ESBLs in this
study was 54.06%. Regarding participant groups and their
relatives, the prevalence was also high (see Table 2). However,
the prevalence of faecal carriage among inpatients was not
signiﬁcantly different from that of their carers (p >0.05).
Similarly, the prevalence of faecal carriage among hospital
workers was not signiﬁcantly different from that of their
household members (p >0.05).
Of the 334 bacteria isolated, 216 (64.67%) were E. coli, 74
(22.15%) were Klebsiella spp., 23 (6.88%) were Enterobacter
spp. and 21 (6.28%) were Citrobacter freundii. Regardless of
group, participants presented similar ESBLs and CTX-M-15
was the most widespread ESBL found in all strains (Table 3).
As demonstrated by the DiversiLab results (see Supple-
mentary material, Fig. S1 and Fig. S2), multiple clones were
seen among ESBL-producing E. coli and using a cut-off of 95%
similarity (vertical dashed red line, Fig. S1) it was possible to
establish six distinct clusters (types I, III, V, VI, VII and X),
indicating the overall close relationship of the isolates, and ﬁve
singleton patterns (types II, IV, VIII, IX and XI) (Table 4). These
six outbreaks occurred between related or non-related
individuals. This ﬁnding conﬁrms that in some cases the
acquisition of E-ESBLs has occurred via a common source or a
common environmental reservoir (hands of hospital workers,
through contaminated surfaces or via food) as described
previously [12–17].
Molecular typing of K. pneumoniae isolates showed them to
be more genotypically diverse than the E. coli isolates. The
repetitive-sequence-based PCR analysis allowed the identiﬁca-
TABLE 1. Characteristics of all participants included in the study
Characteristic
Outpatients
(n = 232)
Inpatients
(n = 208)
Inpatient carers
(n = 63)
Hospital workers
(n = 48)
Household members
(n = 39)
E-ESBL+
n = 104
(45%)
E-ESBL–
n = 128
(55%)
E-ESBL+
n = 140
(67%)
E-ESBL–
n = 68
(33%)
E-ESBL+
n = 36
(57%)
E-ESBL–
n = 27
(43%)
E-ESBL+
n = 21
(44%)
E-ESBL–
n = 27
(56%)
E-ESBL+
n = 18
(46%)
E-ESBL–
n = 21
(54%)
Median age, years (SD) 35  15 36  15.5 37  17.4 41  18 42  14.8 39  13.5 35  6.72 37  10.52 17  13 14  9.24
Male gender (n) 40 60 71 39 6 8 9 16 8 14
Previous hospital admission
Yes 13 23 46 14 5 3 3 3 1 4
No 78 83 88 53 31 24 17 19 14 13
Unknown 13 22 6 1 0 0 1 5 3 4
Previous antimicrobial treatment
Yes 48 56 73 28 7 6 11 6 5 3
No 44 54 52 32 27 19 8 16 11 14
Unknown 12 18 15 8 2 2 2 5 2 4
E-ESBL, extended-spectrum b-lactamase-producing Enterobacteriaceae; E-ESBL–, E-ESBL-negative; E-ESBL+, E-ESBL-positive; SD, standard deviation.
TABLE 2. Primers used for PCR ampliﬁcation
PCR name b-Lactamase(s) targeted Primer name Sequence (5′-3′)
Amplicon
size (bp)
Primer
concentration
(pmol/lL) Reference
Multiplex TEM, TEM variants including, TEM-1 and TEM-2 MultiTSO-T_for CATTTCCGTGTCGCCCTTATTC 800 0.4 [6]
MultiTSO-T_rev CGTTCATCCATAGTTGCCTGAC 0.4
SHV SHV variants, including SHV-1 MultiTSO-S_for AGCCGCTTGAGCAAATTAAAC 713 0.4
MultiTSO-S_rev ATCCCGCAGATAAATCACCAC 0.4
and OXA-1- like OXA-1, OXA-4 and OXA-30 MultiTSO-O_for GGCACCAGATTCAACTTTCAAG 564 0.4
MultiTSO-O_rev GACCCCAAGTTTCCTGTAAGTG 0.4
CTX-M group 1 Variants of CTX-M group 1, including CTX-M-1,
CTX-M-3 and CTX-M-15
CTX-M3G_for GTTACAATGTGTGAGAAGCAG 1050 0.5 [7]
CTX-M3G_rev CCGTTTCCGCTATTACAAAC 0.5
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TABLE 4. Epidemiological data of the 22 selected strains of extended-spectrum b-lactamase (ESBL) -producing Escherichia coli in
Ngaoundere Protestant Hospital
Alternative
identiﬁcation
Type of participants
(department in
which the
participant was
at the time of
sampling)
Type of
relationship/
gender
(age)
Phylogenetic
group
Cluster
type
ST131
PCR PMQR
ISEcp1
element ESBL types
Resistance
to antibiotics
(other than
b-lactam)
f32 Household member
of p3
Daughter (3) D I  –  CTX-M-15, TEM-1 GEN, SXT
20 Maintenance staff
(medicine)
M (42) D I  aac(6′)Ib-cr  CTX-M-15, OXA-1, TEM-1 GEN, SXT
hn50 Inpatient (medicine) F (29) D II  aac(6′)Ib-cr + CTX-M-15, OXA-1, TEM-1 CIP, GEN, SXT
hn89 Inpatient (medicine) M (31) B2 III + aac(6′)Ib-cr + CTX-M-15, OXA-1 CIP, SXT
p13 Nurse (medicine) F (28) B2 IIIa + aac(6′)Ib-cr + CTX-M-15, OXA-1 CIP, SXT
p3 Nurse (surgery) F (41) B2 IIIb + – + CTX-M-15, TEM-1 CIP, SXT
p25 Nurse (intensive
care unit)
F (35) B2 III + –  CTX-M-15, TEM-1 CIP, SXT
hn69 Inpatient (surgery) M (40) B2 IV  aac(6′)Ib-cr + CTX-M-15, OXA-1, TEM-1 CIP, GEN, SXT
p5 Nurse (medicine) F (30) A V  aac(6′)Ib-cr  CTX-M-15, OXA-1 CIP, GEN, NIT,
SXT
16 Maintenance staff
(medicine)
M (38) A V  aac(6′)Ib-cr  CTX-M-15, OXA-1 CIP, GEN, NIT,
SXT
hn82 Inpatient (medicine) M (39) A Va  aac(6′)Ib-cr  CTX-M-15, OXA-1 CIP, GEN, NIT,
SXT
12 Maintenance staff
(operating room)
F (25) A Vb  aac(6′)Ib-cr  CTX-M-15, OXA-1 CIP, GEN, NIT,
SXT
p4 Nurse (medicine) M (38) A Vc  aac(6′)Ib-cr  CTX-M-15, OXA-1 CIP, NIT, SXT
p17 Nurse (surgery) F (27) A VI  aac(6′)Ib-cr  CTX-M-15, OXA-1 CIP, SXT
3 Maintenance staff
(operating room)
M (41) A VIa  aac(6′)Ib-cr  CTX-M-15, OXA-1 CIP, SXT
f2 Household member
of 11
Sister (18) A VII  aac(6′)Ib-cr + CTX-M-15, OXA-1, TEM-1 GEN, SXT
11 Maintenance staff
(maternity)
F (35) A VII  aac(6′)Ib-cr + CTX-M-15, OXA-1, TEM-1 GEN, SXT
ng33 Carer of hn57 Husband (53) A VIII  –  CTX-M-15, OXA-1, TEM-1 CIP, SXT
ng41 Carer of hn69 Wife (35) B1 IX  –  CTX-M-15, OXA-1, TEM-1 CIP, SXT
ng32 Carer of hn57 Sister (55) B1 X  aac(6′)Ib-cr + CTX-M-15, OXA-1, TEM-1 CIP, GEN, SXT
p16 Nurse (medicine) F (33) B1 X  aac(6′)Ib-cr + CTX-M-15, OXA-1, TEM-1 GEN, SXT
hn57 Inpatient (medicine) F (43) D XI  –  CTX-M-15, OXA-1, TEM-1 CIP, GEN, SXT
M, male; F, female; PMQR, plasmid-mediated quinolone-resistance determinants; GEN, gentamicin; SXT, trimethoprim/sulfamethoxazole; CIP, ciproﬂoxacin; Nit, nitrofurantoin.
TABLE 3. Overview of extended-spectrum b-lactamase (ESBL) types produced by Enterobacteriaceae isolated in all groups of
participants
ESBL types (number of isolates)
Strain (n = 334) Outpatients Inpatients Inpatient carers Hospital workers Household members
Citrobacter freundii
(n = 21)
CTX-M-15, OXA-1 (8) CTX-M-15 (2) CTX-M-15, TEM-1 (1)
CTX-M-15, TEM-1 (2) CTX-M-15, OXA-1, TEM-1 (2) CTX-M-15, OXA-1,
TEM-1 (1)
SHV-12, TEM-1 (2) CTX-M-15, TEM-1 (1)
SHV-12, TEM-1 (1)
SHV-12 (1)
Enterobacter spp.
(n = 23)
CTX-M-15, OXA-1,
TEM-1 (14)
CTX-M-15, OXA-1, TEM-1 (5) CTX-M-15, OXA-1,
TEM-1 (2)
SHV-12, TEM-1, OXA-1 (1) SHV-12, TEM-1 (1)
Escherichia coli
(n = 216)
CTX-M-15, OXA-1 (26) CTX-M-15, OXA-1, TEM-1(42) CTX-M-15,
OXA-1, TEM-1 (11)
CTX-M-15, OXA-1 (8) CTX-M-15, TEM-1 (8)
CTX-M-15, TEM-1 (15) CTX-M-15, OXA-1 (30) CTX-M-15, OXA-1 (9) CTX-M-15, OXA-1,
TEM-1 (4)
CTX-M-15, OXA-1,
TEM-1 (5)
CTX-M-15, OXA-1,
TEM-1 (14)
CTX-M-15, TEM-1 (24) CTX-M-15, TEM-1 (8) CTX-M-15, TEM-1 (2)
CTX-M-15 (3) CTX-M-15 (3) CTX-M-15, SHV-12,
OXA-1, TEM-1(1)
SHV-12, TEM-1 (1) CTX-M-15 (1)
SHV-12 (1)
Klebsiella spp.
(n = 74)
CTX-M-15, SHV-1, TEM-1 (8) CTX-M-15, SHV-1, TEM-1 (13) CTX-M-15, SHV-1,
TEM-1 (7)
CTX-M-15, SHV-1, TEM-1 (2) CTX-M-15, SHV-1,
TEM-1 (1)
CTX-M-15, TEM-1 (8) CTX-M-15, TEM-1 (6) CTX-M-15, SHV-1,
OXA-1, TEM-1(1)
CTX-M-15, OXA-1,
TEM-1 (2)
CTX-M-15 (1)
CTX-M-15, OXA-1, TEM-1 (5) CTX-M-15, SHV-1,
OXA-1, TEM-1(5)
CTX-M-15, TEM-1 (1) CTX-M-15, OXA-1 (1)
CTX-M-15, OXA-1 (2) CTX-M-15, OXA-1, TEM-1 (4) CTX-M-15, OXA-1 (1) CTX-M-15, TEM-1 (1)
CTX-M-15, SHV-1,
OXA-1, TEM-1 (1)
CTX-M-15, SHV-12, TEM-1 (1) SHV-12 (1)
SHV-12 (1) CTX-M-15 (1)
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tion of two clusters and 17 unique proﬁles (see Supplementary
material, Fig. S3 and Fig. S4). Our results emphasize the high
endemicity of CTX-M-15 producers in the study setting
(demonstrated by the very high prevalence in all participant
categories). In addition, these ﬁndings could also explain the
dramatic increase in the prevalence of faecal carriage of
E-ESBLs previously observed in the same area during two non-
outbreak periods separated by 1 year (in 2009 and 2010) [3,4]
(and data of this study). Moreover, examination of the different
clusters (III, V and VI) showed that different strains of E. coli
produced the same type of b-lactamase, indicating that the
spread does not occur by strain but by another mode of
dissemination (e.g. dissemination by plasmids: further studies
are ongoing to clarify this).
The PCR for the pabB allele of ST131 status identiﬁed
cluster III with four related isolates as belonging to ST131. The
ST131 status was conﬁrmed by multilocus sequence typing. In
addition, isolates from this cluster could be assigned to
phylogenetic group B2. The remaining ESBL-producing E. coli
isolates (negative by PCR for pabB) belonged to phylogenetic
groups A, B2, D and B1 (ten, one, four and three isolates,
respectively). Interestingly, strains that belonged to the same
phylogenetic group and clustered together showed a similar
resistance proﬁle to the antibiotics tested (Table 4). Many of
the E. coli carrying blaCTX-M-15 from different countries in
Europe and North America are homogeneously grouped as
E. coli O25:H4-ST131 [11,18–20]. In addition, in all blaCTX-M-15
tested, the aac(6′)-Ib-cr gene was carried by 16 strains (16/22)
and the ISEcp1 element was found in nine of the strains
analysed (9/22). One study has reported that CTX-M ESBL
genes are often associated with an ISEcp1 element, which may
provide a higher level of expression of the plasmid-located
blaCTX-M genes and facilitate the spread of resistance [21]. Our
study provides the ﬁrst evidence for the presence of an E. coli
ST131 clone in Cameroon. Strict hygiene measures, staff
training to improve hand-washing procedures and changes to
the antibiotic policy are essential to limit the spread of these E-
ESBLs in hospitals and the community.
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Figures S1 and S2. DNA ﬁngerprinting of the 22 investigated
extended-spectrum b-lactamase (ESBL) -producing Escherichia
coli isolates in Ngaoundere Protestant Hospital (NH). Den-
drogram, virtual gel image and similarity matrix demonstrate
strain clustering. The horizontal bar on the bottom left
indicates the percentage similarity within the strains. A cut-off
of 95% similarity (vertical dashed red line) was chosen for
determination of clonal relatedness. ICU, Intensive care unit.
Figures S3 and S4. DNA ﬁngerprinting of the 22 investigated
extended-spectrum b-lactamase (ESBL) -producing Klebsiella
pneumoniae isolates in Ngaoundere Protestant Hospital (NH)
and Ngaoundere Regional Hospital (RH). *hn59: inpatient
identiﬁed with a strain of Escherichia coli, but the two carers
(ng36 and ng37) of this patient carried K. pneumoniae isolates.
The horizontal bar on the bottom left indicates the percentage
similarity within the strains. A cut-off of 95% similarity (vertical
dashed red line) was chosen for determination of clonal
relatedness.
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